― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the
First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10) Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor
– Loan Originations of $1.3 Billion – – Net Income of $3.2 Million – – Diluted Earnings Per Share of $0.23 – MURRAY, Utah, April 30, 2025 (GLOBE NEWSWIRE) — FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced results for the quarter ended March 31, 2025. First
NORTH LIBERTY, Iowa, April 30, 2025 (GLOBE NEWSWIRE) — Heartland Express, Inc. (Nasdaq: HTLD) announced today financial results for the three months ended March 31, 2025. Three months ended March 31, 2025: Operating Revenue of $219.4 million, Net Loss of $13.9 million, Basic Loss per Share of $0.18, Operating Ratio of 106.8% and 107.1% Non-GAAP
FDA stated as part of a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval BLA seeking accelerated approval planned to be submitted by year-end 2025; global Phase 3 study planned to initiate in mid-2025 Completed dosing in adolescent
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseases Positive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson’s disease (PD) Additional ACI-7104.056 Phase 2 interim
INDIANAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) — Kite Realty Group (NYSE: KRG), a premier owner and operator of high-quality, open-air grocery-anchored centers and vibrant mixed-use assets, reported today its operating results for the first quarter ended March 31, 2025. For the quarters ended March 31, 2025 and 2024, net income attributable to common shareholders was
Paris (France), April 29, 2025 A SOLID START TO THE YEAR, WITH SUCCESSFUL REFINANCING AND VESSEL CAPACITY AGREEMENT TERMINATED Q11 Revenue2 $301M (+10%) Adjusted EBITDA2 $143M (+35%) Net Cash Flow $(20)M (vs $30M) Including a $42M interest payment in March 2025 (historically paid in Q2) Sophie Zurquiyah, Chief Executive Officer of Viridien: “The first quarter
BATON ROUGE, La., April 24, 2025 (GLOBE NEWSWIRE) — Business First Bancshares, Inc. (NASDAQ: BFST) (Business First), parent company of b1BANK, today announced its unaudited results for the quarter ended March 31, 2025. Business First reported net income available to common shareholders of $19.2 million or $0.65 per diluted common share, increases of $4.1 million
RED BANK, N.J., April 24, 2025 (GLOBE NEWSWIRE) — OceanFirst Financial Corp. (NASDAQ:OCFC) (the “Company”), the holding company for OceanFirst Bank N.A. (the “Bank”), announced net income available to common stockholders of $20.5 million, or $0.35 per diluted share, for the quarter ended March 31, 2025, a decrease from $27.7 million, or $0.47 per diluted